SANTEN PHARMACEUTICAL CO.,LTD. Logo

SANTEN PHARMACEUTICAL CO.,LTD.

A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.

4536 | T

Overview

Corporate Details

ISIN(s):
JP3336000009
LEI:
Country:
Japan
Address:
大阪市北区大深町4番20号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santen Pharmaceutical Co., Ltd. is a global pharmaceutical company specializing in ophthalmology. The company engages in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. Its portfolio addresses a wide range of ocular conditions, including glaucoma, dry eye, and infections. Serving patients, consumers, and medical professionals, Santen operates in over 60 countries and regions worldwide, guided by its vision of contributing to "Happiness with Vision" for people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 07:02
Registration Form
確認書
Japanese 8.7 KB
2025-11-10 07:01
Interim Report
半期報告書-第114期(2025/04/01-2026/03/31)
Japanese 366.6 KB
2025-10-15 03:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-09-12 04:58
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.9 KB
2025-08-13 03:24
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-15 04:38
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-25 04:08
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-24 09:22
Remuneration Information
臨時報告書
Japanese 32.1 KB
2025-06-23 08:29
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-23 08:28
Registration Form
確認書
Japanese 8.5 KB
2025-06-23 08:27
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 2.2 MB
2025-06-13 04:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-04-15 06:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB
2025-03-13 03:29
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.8 KB
2025-02-14 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB

Automate Your Workflow. Get a real-time feed of all SANTEN PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANTEN PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANTEN PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GREEN CROSS WellBeing Corporation Logo
Develops personalized nutrition solutions, from prescription injections to supplements & cosmetics.
South Korea
234690
Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America
GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America
GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain
GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia
GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America
GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea
036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America
GYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.